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Abstract
A malaria vaccine as part of the integrated malaria control and elimination efforts will have a major impact on
public health in sub-Sahara Africa. The first malaria vaccine, RTS,S, now enters pilot implementation in three African
countries. These pilot implementation studies are being initiated in Kenya, Malawi, and Ghana to inform the
broader roll-out recommendation. Based on the malaria vaccine clinical trial experiences, key ethical practices for
effective clinical trial research in low-resource settings are described. For successful vaccine integration into malaria
intervention programs, the relational dynamics between researchers and trial communities must be made explicit.
Incorporating community values and returning to research practices that serve the intended benefactors are key
strategies that address the human realities in large-scale clinical trials and pilot implementation, leading to positive
public health outcomes.
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Introduction
In 2017 malaria was attributed to 435,000 deaths and
nearly half the world’s population was identified to be at
risk of infection. Malarial disease carries an immense
public health burden, and those at the highest risk for
malaria are children living in endemic regions; it is esti-
mated that 266,000 children under 5 years of age died
from infection in 2017 [1]. Since the year 2000, signi-
ficant work has been done towards reducing the burden
of malaria, with much progress made [2]. This success is
largely owed to insecticide-treated bed nets (INTs), in-
door residual spraying (IRS), and artemisinin-based
combination therapy (ACTs), contributing to a 40%
reduction in clinical disease and a 50% reduction in
Plasmodium falciparum infection [2]. While these
figures looked promising, they were still far short of the
WHO target of 75% reduction in malaria burden by the
year 2015 [3]. In order to achieve this reduction, more
tools are needed, including effective vaccines, especially
in high-transmission areas.
Currently, a number of vaccines are in the pipeline for
malaria, in both pre-clinical and clinical development,
targeting both children and pregnant women [4]. These
target varying stages of the malaria parasite’s life-cycle
and are categorized as pre-erythrocytic vaccines (PEV),
blood-stage vaccines (BSV), transmission-blocking vac-
cines (MSTBV), and combination vaccines. Despite a
robust pipeline, long-lasting sterile immunity against
malaria with these vaccines is unlikely and a vaccine will
instead serve as a tool to be utilized in combination with
other intervention methods. Due to the high burden of
disease, a vaccine with a modest level of protection
would translate into a significant impact given almost
half a million annual deaths. Today there is cautious
optimism for a modestly effective vaccine called RTS,S
developed in partnership by PATH Malaria Vaccine
Initiate (MVI), GlaxoSmithKline (GSK), and a number
of academic and research institutions.
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RST,S is a pre-erythrocytic vaccine that has been in
development since 1987 and concluded phase III testing
in early 2014. The phase III studies adhered stringently
to all aspects of formal research requirements, such as
Good Clinical Practice (GCP) and Good Laboratory
Practice (GLP) guidelines; every effort was made to
standardize the process. This large multi-national trial
enrolled 15,459 infants and was carried out at 11 clinical
trials centers in seven countries (Burkina Faso, Gabon,
Malawi, Mozambique, Ghana, Tanzania, Kenya). RTS,S
has been shown to be most effective in children aged 5–17
months, who receive three doses of the vaccine and then a
booster at 20months of age, reducing the cases of severe
malaria by 36% [5].
The next step for this vaccine is pilot study roll-out in
Kenya, Ghana, and Malawi. In these three selected coun-
tries the Ministries of Health will work together with the
WHO to establish the Malaria Vaccine Implementation
Program (MVIP). In addition to the efficacy and safety
profile, these pilot implementation studies will shed light
on the programmatic feasibility of RTS,S in real-life set-
tings, a factor modeling studies have identified to be a
critical component of reaching a significant public health
impact [6, 7]. To adequately assess the feasibility of
RTS,S in real-life settings, researchers must engage local
communities and carefully consider the ethics and pro-
cesses of undertaking MVIP in different sociocultural
settings. This means acknowledging relational ethics in
vaccine studies, community dynamics, and vaccine up-
take and a commitment to long-term monitoring of the
malaria vaccine program.
The role of relationship in research studies
Previous RTS,S studies have placed a lot of emphasis on
adhering to regulatory requirements and formal research
ethics. What we can learn from other vaccine trials is
that the emphasis of formal research ethics is as import-
ant as close engagement of the clinical trial team with
the community [8]. Taking the time to build intimate re-
lationships fostering shared ownership of the research
synergistically and effectively complements the scientific
protocols and formal ethical procedures. Relational eth-
ics and shared ownership play a significant role in deter-
mining the effectiveness of malaria vaccine studies.
Much of the success of a malaria vaccine trial in The
Gambia has been attributed to intimate kinship-like rela-
tionships between the trial community and field workers
[8]. This kind of a relational interaction fosters close col-
laboration between researchers and communities to con-
front social and political circumstances. Through this
interaction it was found that even in contexts where par-
ental awareness of the RTS,S vaccine was low, there
remained a keen desire to enrol children in RTS,S vac-
cination programs if made available. Based on this work,
recommendations have been made around disseminating
information specifically to mothers about the vaccine
that considers the social and political realities that par-
ticipants inhabit [9]. In Tanzania, stakeholders have
expressed a positive opinion of the vaccine but have
drawn attention to the need for an inclusive communica-
tion strategy that incorporates communities and local
health care professionals in a culturally appropriate way
for that positive opinion to endure [10]. These examples
shed light on the need to critically assess processes and
ethical conduct during large-scale clinical trials to ensure
effective incorporation of the tool into integrated malaria
control and elimination programs, considerations that
stretch beyond a confident safety profile.
The international community has set ambitious goals
for malaria by 2030 and has put RTS,S on the table as a
tool to be used in an integrated approach with other
malaria interventions [11]. As we move forward these
relational aspects are of particular importance to foster a
concerted effort across scientific disciplines and stake-
holders from varying sociocultural backgrounds. By
harnessing lessons learned from previous malaria vac-
cine clinical trial experiences, effective integration of this
vaccine into malaria control programs is possible in
richly diverse sociocultural contexts.
Communities and vaccine uptake
Strong community relations and local engagement have
the potential to bring autonomy, transparency, and
respect to the work of the researchers. From a utilitarian
perspective, it can strengthen the RTS,S malaria pilot
study in the selected sites. The RTS,S phase III studies
had Community Advisory Boards (CABS) which consisted
of influential community members who supported the
communication between communities and researchers.
These have been effective and therefore need to be further
strengthened to involve additional stakeholders with inte-
rests in the community and the children’s welfare at large
[12]. Acknowledging fundamental intelligence within com-
munities and translating this into the execution of these
pilot implementation studies will propel us toward the goal
of RTS,S informed choice and acceptance within the com-
munity setting. Listening to the voices of the community
and integrating these into the study design leads to greater
research vaccine uptake [13–15]. Failure to do so heightens
the power disparity and reduces optimal integration.
Long-term monitoring of study sites
In malaria endemic regions, the risk of mortality shifts
to morbidity at around age five. However, modeling
studies suggest that severe malaria is likely to occur at
later ages in children living in RTS,S research sites [6].
This places an emphasis on the need for long-term mo-
nitoring and evaluation of research sites. This sustained
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long-term monitoring is often resource consuming but
is critical in understanding the impact of interventions
and shifting disease epidemiology. Through the collec-
tion of narratives and genuinely engaging with commu-
nity members to share their experiences, potential risks
can be followed-up, flagged, and clinically investigated.
Ethical conduct does not only conclude at obtaining in-
formed consent, it continues into research, monitoring,
and implementation. The transition in age for severe
malaria needs to be explained to the communities—that
it is not related to the vaccine deployment but rather a
change in the disease prevalence. This, if not explained
well, may affect the uptake of the vaccine over time.
Some may challenge the feasibility of relational engage-
ment that is context-sensitive to the MVIP sites; however,
substantive evidence indicates that close community en-
gagement is a favorable approach to the research in ques-
tion and does not introduce biases and dependencies of
concern at the ethical or research outcome levels [16–19].
We therefore argue that this can be streamlined and, on the
contrary, strengthen the efficiency of the pilot studies.
Communities can always provide key insights and facilitate
researcher familiarization with the research setting. This, in
turn, allows for effective planning and site organization, two
factors that have been identified to be key contributors to
streamlining the efficiency of clinical trials [20]. Through
encouraging dialogue during initial introductions and buil-
ding relationships that encourage communities to speak up,
to feel safe when doing so, and report when adverse events
occur, time will be saved and researchers can ensure a more
benevolent process as the monitoring is intrinsic to the
study. Previous studies looking at the benefits of community
engagement support these claims, suggesting enhanced
ownership of the research by local communities strengthens
the effectiveness of the research [21–24]. Combating the
thorny dynamics of malarial disease without this ap-
proach can lead to the aggravation of adverse events
and mistrust in the community of vaccination research
as a whole [21, 24]. Therefore, it is the responsibility of
those who will conduct the pilot implementation stu-
dies to call upon the communities to work alongside
them for support when incorporating the distinctive
values and social and cultural practices to build trust
and ultimately strengthen the social value of RTS,S.
Conclusions
Reaching coverage across the target population and crea-
ting an integrated, tailored approach alongside other
malaria interventions will determine the extent of the
public health impact a malaria vaccine will have [6, 25].
This means a keen awareness of local prevention and
treatment practices as well as transmission patterns.
Vaccines in the development pipeline targeting parasitic
diseases cannot be compared to the well-known highly
efficacious vaccines of the childhood diseases caused by
bacteria and viruses. Parasites have very complex life cy-
cles with sexual and asexual development cycles in differ-
ent niches of the hosts, and thus current efforts lead to
only partially efficacious vaccines that still show a
significant alleviation of the disease burden [26]. Conse-
quently, working with partially effective vaccines, and
tools in general, heightens the emphasis we must place on
rooting research in the local social realities to best under-
stand compliance and adherence. RTS,S has an excellent
opportunity to set the global stage for shared research
ownership, effective community engagement, and the
development of an integrated, tailored approach to reduce
the disease burden.
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